Journal
MOLECULES
Volume 18, Issue 6, Pages 6469-6490Publisher
MDPI
DOI: 10.3390/molecules18066469
Keywords
biomolecules; Cerenkov luminescence imaging; desferrioxamine B; dosimetry; positron emission tomography (PET); Zr-89
Funding
- Fonds der Chemischen Industrie
Ask authors/readers for more resources
Molecular imaging-and especially Positron Emission Tomography (PET)-is of increasing importance for the diagnosis of various diseases and thus is experiencing increasing dissemination. Consequently, there is a growing demand for appropriate PET tracers which allow for a specific accumulation in the target structure as well as its visualization and exhibit decay characteristics matching their in vivo pharmacokinetics. To meet this demand, the development of new targeting vectors as well as the use of uncommon radionuclides becomes increasingly important. Uncommon nuclides in this regard enable the utilization of various selectively accumulating bioactive molecules such as peptides, antibodies, their fragments, other proteins and artificial structures for PET imaging in personalized medicine. Among these radionuclides, Zr-89 (t(1/2) = 3.27 days and mean E beta+ = 0.389 MeV) has attracted increasing attention within the last years due to its favorably long half-life, which enables imaging at late time-points, being especially favorable in case of slowly-accumulating targeting vectors. This review outlines the recent developments in the field of Zr-89-labeled bioactive molecules, their potential and application in PET imaging and beyond, as well as remaining challenges.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available